MedTrace Logo

Subcutaneous Recombinant Human Hyaluronidase: Workflow Analysis and Emergency Department Design

NCT01020513 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2013-12-11

No results posted yet for this study

Summary

This is an observational study examining the workflow dynamics and training requirements that support effective use of subcutaneous hydration delivery (a newly FDA approved Baxter product) compared to standard intravenous hydration/medication delivery. Emergency departments already using both Subcutaneous Recombinant Human Hyaluronidase and standard IV hydration will be enrolled. Patients will be receiving the hydration method selected by their emergency department physician and the investigators will then observe:

1. Patient Throughput

* Efficiency of patient care and treatment areas
* Safety of patient care and treatment areas
* Support Service processes that impact patient flow
2. Clinical Outcomes

* Time to conversion from dehydration to hydration'
* Rate of complications
3. Satisfaction

* Staff satisfaction with Subcutaneous hydration vs. Intravenous hydration
* Patient satisfaction with Subcutaneous hydration vs. Intravenous hydration

Conditions

Sponsors & Collaborators

Principal Investigators

  • John M Fontanesi, PhD · UCSD School of Medicine, Department of General Internal Medicine

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2011-01-31
Completion
2011-02-28

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01020513 on ClinicalTrials.gov